Reata Pharmaceuticals, Inc. Announces Presentation of KIDNEYCODE Program at the American Society of Nephrology Kidney Week 20...
October 15 2020 - 6:45AM
Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”)
announced today the upcoming presentation of
K
IDNEYCODE: A Genetic Testing Program for Patients
with Chronic Kidney Disease, as an e-poster to be presented at the
American Society of Nephrology (ASN) Kidney Week 2020 Reimagined.
This e-poster will be presented on Thursday, October 22, 10:00 a.m.
EDT. Details and a link to access the presentation are as follows:
ePoster Session Session Title: Genetic Diseases of
the Kidneys: Non-Cystic - 1 Session Release Date, Time: Thursday,
October 22, 10:00 a.m. EDT ePoster #: PO1612Access link:
https://www.asn-online.org/education/kidneyweek/2020/posters-access.aspx
“Reata is proud to present important data from
its KIDNEYCODE program at this year’s ASN Kidney
Week Reimagined,” said Seemi Khan, MD, MPH, Reata’s Chief Medical
Officer. “Today, with more than 1,000 KIDNEYCODE
tests administered across the U.S., the value of genetic testing to
nephrologists, patients, and families is clear and compelling. We
look forward to this opportunity to shed light on that value at
this prestigious forum.”
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone methyl
(“bardoxolone”) and omaveloxolone, target the important
transcription factor Nrf2 that promotes the resolution of
inflammation by restoring mitochondrial function, reducing
oxidative stress, and inhibiting pro-inflammatory signaling.
Bardoxolone and omaveloxolone are investigational drugs,
and their safety and efficacy have not been established by any
agency.
Contact:Reata Pharmaceuticals,
Inc.(972) 865-2219http://reatapharma.com
Investors:Vinny
JindalVice President, Investor Relations and Corporate
Communications(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Sep 2023 to Sep 2024